Stocks
Intellia Therapeutics (NTLA) EBITDA margin US GAAP (year values) |
|||||||||
| 2021 | 2022 | 2023 | 2024 | 2025 | LTM ? | CAGR 5 years ? | |||
| EBITDA margin, % | ? | -789.5% | -864.5% | -1 396% | -905.3% | -586.3% | -601.7% | ||
| Changes by years, y/y, % | -565pp | -75pp | -531pp | +490pp | +319pp | +21.2% | |||
Intellia Therapeutics. EBITDA margin, %
Intellia Therapeutics. EBITDA margin, changes, pp
Intellia Therapeutics (NTLA) EBITDA margin US GAAP (quarter values) |
||||||||
| 2025Q1 | 2025Q2 | 2025Q3 | 2025Q4 | 2026Q1 | LTM ? | |||
| EBITDA margin, % | ? | -711.5% | -754.8% | -699.4% | -414.5% | -653.4% | -601.7% | |
| Changes by years, y/y, % | -326pp | +1 206pp | +861pp | +625pp | +58pp | |||
| Changes by quarters, q/q, % | +328pp | -43pp | +55pp | +285pp | -239pp | |||
